A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The investigator believes that injecting Copaxone into tumors will help participants immune
system fight cancer. This has been studied in mice and has shown encouraging results.
Copaxone is a safe medication currently used to treat Multiple Sclerosis (MS) and has very
few side effects. To be considered for this trial a tumor must be easy to be injected and
must be at least the size of a pea. Participants will be closely monitored for any side
effects. Tissue from before surgery will be compared to tissue after the treatment and
surgery to be checked for immune response and anti-tumor effects.